Adaptive Biotechnologies (ADPT) Liabilities and Shareholders Equity (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $505.9 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 0.96% year-over-year to $505.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 billion (down 8.56% YoY) and the FY2025 annual result came in at $512.7 million, down 4.94% from the prior year.
• Liabilities and Shareholders Equity slipped to $505.9 million in Q1 2026 per ADPT's latest filing, from $512.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $884.2 million in Q3 2022, with the low at $490.6 million in Q3 2025.
• Average Liabilities and Shareholders Equity over 5 years is $656.5 million, with a median of $620.3 million recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity decreased 23.5% in 2024 and fell 0.96% in 2026.
• Adaptive Biotechnologies' Liabilities and Shareholders Equity stood at $856.6 million in 2022, then declined by 22.82% to $661.1 million in 2023, then fell by 18.42% to $539.4 million in 2024, then dropped by 4.94% to $512.7 million in 2025, then dropped by 1.32% to $505.9 million in 2026.
• Business Quant data shows ADPT's Liabilities and Shareholders Equity at $505.9 million in Q1 2026, $512.7 million in Q4 2025, and $490.6 million in Q3 2025.